Esperion to Participate in Upcoming Jefferies London Healthcare Conference
Esperion (NASDAQ: ESPR) has announced its participation in the 2024 Jefferies London Healthcare Conference scheduled for Tuesday, November 19, 2024, at 11:30 a.m. ET. The event will be webcasted live on Esperion's investor and media section website, with replay access available approximately two hours after the call and archived for 90 days.
Esperion focuses on developing innovative medicines for cardiovascular and cardiometabolic diseases, particularly targeting high cholesterol. The company aims to support healthcare providers in reducing LDL-cholesterol levels as effectively as possible, addressing the needs of millions of patients whose health requirements are not met by current standards.
Esperion (NASDAQ: ESPR) ha annunciato la sua partecipazione al 2024 Jefferies London Healthcare Conference, previsto per martedì 19 novembre 2024, alle 11:30 ET. L'evento sarà trasmesso in diretta streaming sul sito web dedicato agli investitori e ai media di Esperion, con accesso alla registrazione disponibile circa due ore dopo la chiamata e archiviata per 90 giorni.
Esperion si concentra sullo sviluppo di medicine innovative per malattie cardiovascolari e cardiometaboliche, mirate particolarmente all'ipercolesterolemia. L'azienda si propone di supportare i fornitori di servizi sanitari nella riduzione dei livelli di LDL-colesterolo nel modo più efficace possibile, affrontando le esigenze di milioni di pazienti le cui necessità sanitarie non sono soddisfatte dagli attuali standard.
Esperion (NASDAQ: ESPR) ha anunciado su participación en la Conferencia de Salud de Jefferies Londres 2024, programada para el martes 19 de noviembre de 2024, a las 11:30 a.m. ET. El evento se transmitirá en vivo a través del sitio web de inversores y medios de Esperion, con acceso a la repetición disponible aproximadamente dos horas después de la llamada y archivada durante 90 días.
Esperion se enfoca en desarrollar medicamentos innovadores para enfermedades cardiovasculares y cardiometabólicas, dirigiéndose especialmente al colesterol alto. La compañía tiene como objetivo apoyar a los proveedores de atención médica a reducir los niveles de LDL-colesterol de la manera más efectiva posible, abordando las necesidades de millones de pacientes cuyas demandas de salud no están satisfechas por los estándares actuales.
Esperion (NASDAQ: ESPR)는 2024 제프리스 런던 헬스케어 콘퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2024년 11월 19일 화요일 오전 11시 30분 ET에 예정되어 있습니다. 이벤트는 Esperion의 투자자 및 미디어 섹션 웹사이트에서 라이브로 방송되며, 통화 후 약 2시간 후에 다시 볼 수 있는 접근이 가능하고 90일 동안 아카이브됩니다.
Esperion은 고콜레스테롤을 목표로 하여 심혈관 및 심혈관 대사 질환을 위한 혁신적인 약물을 개발하는 데 집중하고 있습니다. 이 회사는 현재 기준으로 충족되지 않는 수백만 환자의 건강 요구를 해결하기 위해 가능한 한 효과적으로 LDL-콜레스테롤 수치를 줄이는 데 있어 의료 서비스를 제공하는 이들을 지원하는 것을 목표로 하고 있습니다.
Esperion (NASDAQ: ESPR) a annoncé sa participation à la Conférence Santé Jefferies de Londres 2024, prévue pour le mardi 19 novembre 2024, à 11h30 ET. L'événement sera diffusé en direct sur le site web dédié aux investisseurs et aux médias d'Esperion, avec accès à la rediffusion disponible environ deux heures après l'appel et archivée pendant 90 jours.
Esperion se concentre sur le développement de médicaments innovants pour les maladies cardiovasculaires et cardiométaboliques, en ciblant particulièrement l'hypercholestérolémie. L'entreprise vise à soutenir les prestataires de soins de santé dans la réduction des niveaux de LDL-cholestérol de la manière la plus efficace possible, répondant ainsi aux besoins de millions de patients dont les exigences sanitaires ne sont pas satisfaites par les normes actuelles.
Esperion (NASDAQ: ESPR) hat seine Teilnahme an der 2024 Jefferies London Healthcare Conference angekündigt, die für Dienstag, den 19. November 2024, um 11:30 Uhr ET geplant ist. Die Veranstaltung wird live auf der Investor- und Medienwebsite von Esperion übertragen. Der Zugriff auf die Wiederholung wird ungefähr zwei Stunden nach dem Anruf möglich sein und für 90 Tage archiviert.
Esperion konzentriert sich auf die Entwicklung innovativer Medikamente für kardiovaskuläre und kardiometabolische Erkrankungen, insbesondere zur Bekämpfung von hohem Cholesterin. Das Unternehmen hat sich zum Ziel gesetzt, Gesundheitsdienstleister bei der möglichst effektiven Senkung der LDL-Cholesterinwerte zu unterstützen und die Bedürfnisse von Millionen von Patienten zu adressieren, deren Gesundheitsanforderungen von den aktuellen Standards nicht erfüllt werden.
- None.
- None.
ANN ARBOR, Mich., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 11:30 a.m. ET.
The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on X at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
When is Esperion (ESPR) presenting at the Jefferies London Healthcare Conference 2024?
How long will Esperion's (ESPR) webcast replay be available?
What is Esperion's (ESPR) main focus in healthcare?
Where can investors watch Esperion's (ESPR) Jefferies Conference presentation?
